Clinical impact through AI Assisted MS care
The CLAIMS project aims to address the urgent need for more data-driven and personalized care for people with MS (pwMS). To this end, our mission is to develop, validate, and seek regulatory approval for a companion platform that provides a holistic view of each patient by visualizing both existing and new biomarker data, as well as predict disease trajectories under different treatment scenarios. Powered by deep-learning-based disease subtyping and progression models, this platform aims to enhance the precision of MS care, extending the patients’ quality-adjusted life years, and reducing the economic burden on both individuals and society.
1
Development of new measurement tools for biomarkers to better disentangle Progression Independent of Relapse Activity (PIRA) and Relapse Associated Worsening (RAW) based on MRI and digital health tools.
2
3
Integration of the measurement tools and AI-based models into a companion diagnostic platform, which can be integrated in the clinical workflow.
4
Validation and submission for regulatory approval of the companion diagnostic platform to ensure a sustainable adoption in the market.
News
RECLAIM study protocol is published – cohort update
As we dive into the second half of 2025, we are excited to share the collective progress made by the CLAIMS consortium in the RECLAIM clinical study (NCT06280755). One of the key milestones we are proud to announce is the peer-reviewed publication of the RECLAIM study protocol: https://doi.org/10.3389/fneur.2025.1557947 RECLAIM STUDY…
Quantifying smouldering pathology – One scan at a time
A primary objective of CLAIMS is to develop tools that enhance the monitoring of disease progression in patients with Multiple Sclerosis. In this regard, the team working on Work Package 4 aims to develop, validate, and implement novel MRI image analysis pipelines to more effectively distinguish between active inflammation and…
Milestones of the RECLAIM Study – Over 900 Patients and 13,000 MRI Scans
As we close out 2024, we are proud to reflect on the significant progress we have made over the past year with the RECLAIM study. We now have longitudinal data from over 900 patients, including more than 13,000 MRI scans, all of which have been quantitatively analysed. RECLAIM (NCT06280755) aims…
